The cardiovascular drugs market would grow at a CAGR of 4.52% over the predicted time frame. The market is expected to increase in value from US$ 162.64 Bn in 2022 to US$ 231.7 Bn in 2030.
The on cardiovascular drugs Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2037
Report Scope of the Cardiovascular Drugs Market
| Report Coverage | Details |
| Market Size in 2022 | USD 162.64 Billion |
| Market Size by 2030 | USD 231.7 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 4.52% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Drug Type, Disease Indication, Route of Administration, Drug, Mode of Purchase, End Users, Geography |
A recent report provides crucial insights along with application based and forecast information in the Global Cardiovascular drugs Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Cardiovascular drugs market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Cardiovascular drugs market are included as given below:
Cardiovascular drugs Market Key Players
- Bristol-Myers Squibb Company
- Bayer AG
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc.
- Novartis AG
- Merck & Co.
- AstraZeneca
- Sanofi
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche
Market Segments
By Drug Type
- Antihypertensive
- Anticoagulants
- Antihyperlipidemic
- Antiplatelet Drugs
- Others
By Disease Indication
- Hypertension
- Coronary Artery Disease
- Hyperlipidaemia
- Arrhythmia
- Others
By Route of Administration
- Oral
- Parenteral
- Others
By Drug Classification
- Branded Drugs
- Generic Drugs
By Mode of Purchase
- Prescription-Based Drugs
- Over-The-Counter Drugs
By End Users
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global cardiovascular drugs market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the cardiovascular drugs market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. End Users Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cardiovascular Drugs Market
5.1. COVID-19 Landscape: Cardiovascular Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cardiovascular Drugs Market, By Drug Type
8.1. Cardiovascular Drugs Market, by Drug Type, 2022-2030
8.1.1. Antihypertensive
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Anticoagulants
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Antihyperlipidemic
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Antiplatelet Drugs
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Cardiovascular Drugs Market, By Disease Indication
9.1. Cardiovascular Drugs Market, by Disease Indication, 2022-2030
9.1.1. Hypertension
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Coronary Artery Disease
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Hyperlipidaemia
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Arrhythmia
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Cardiovascular Drugs Market, By Route of Administration
10.1. Cardiovascular Drugs Market, by Route of Administration, 2022-2030
10.1.1. Oral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Parenteral
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Cardiovascular Drugs Market, By Drug Classification
11.1. Cardiovascular Drugs Market, by Drug Classification, 2022-2030
11.1.1. Branded Drugs
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Generic Drugs
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Cardiovascular Drugs Market, By Mode of Purchase
12.1. Cardiovascular Drugs Market, by Mode of Purchase, 2022-2030
12.1.1. Prescription-Based Drugs
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Over-The-Counter Drugs
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Cardiovascular Drugs Market, By End Users
13.1. Cardiovascular Drugs Market, by End Users, 2022-2030
13.1.1. Hospital Pharmacies
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Online Pharmacies
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Retail Pharmacies
13.1.3.1. Market Revenue and Forecast (2017-2030)
13.1.4. Others
13.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Cardiovascular Drugs Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.6. Market Revenue and Forecast, by End Users (2017-2030)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.8.1. Market Revenue and Forecast, by End Users (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.1.10. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.1.11. Market Revenue and Forecast, by End Users (2017-2030)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.6. Market Revenue and Forecast, by End Users (2017-2030)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.9. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.10. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.10.1. Market Revenue and Forecast, by End Users (2017-2030)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.12. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.13. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.14. Market Revenue and Forecast, by End Users (2017-2030)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.15.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.15.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.15.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.16. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.16.1. Market Revenue and Forecast, by End Users (2017-2030)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.2.17.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.2.17.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.2.17.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.2.18. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.2.18.1. Market Revenue and Forecast, by End Users (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.6. Market Revenue and Forecast, by End Users (2017-2030)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.9. Market Revenue and Forecast, by End Users (2017-2030)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.11. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.11.1. Market Revenue and Forecast, by End Users (2017-2030)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.12.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.12.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.12.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.12.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.12.6. Market Revenue and Forecast, by End Users (2017-2030)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.3.13.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.3.13.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.3.13.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.3.13.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.3.13.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.9. Market Revenue and Forecast, by End Users (2017-2030)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.11. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.12. Market Revenue and Forecast, by End Users (2017-2030)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.13.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.13.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.13.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.13.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.13.6. Market Revenue and Forecast, by End Users (2017-2030)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.4.14.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.4.14.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.4.14.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.4.14.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.4.14.6. Market Revenue and Forecast, by End Users (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.6. Market Revenue and Forecast, by End Users (2017-2030)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.7.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.7.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.7.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.8. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.8.1. Market Revenue and Forecast, by End Users (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Drug Type (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Disease Indication (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Route of Administration (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Drug Classification (2017-2030)
14.5.9.5. Market Revenue and Forecast, by Mode of Purchase (2017-2030)
14.5.9.6. Market Revenue and Forecast, by End Users (2017-2030)
Chapter 15. Company Profiles
15.1. Bristol-Myers Squibb Company
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Bayer AG
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Pfizer Inc
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Janssen Pharmaceuticals, Inc.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Novartis AG
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Merck & Co.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. AstraZeneca
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Sanofi
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Gilead Sciences, Inc
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. F. Hoffmann-La Roche
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments